Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
Theratechnologies downgraded to Hold from Buy at Canaccord » 07:53
07/29/21
07/29
07:53
07/29/21
07:53
THTX

Theratechnologies

$3.75 /

+0.19 (+5.34%)

Canaccord Genuity analyst…

Canaccord Genuity analyst Edward Nash downgraded Theratechnologies to Hold from Buy with a price target of $3, down from $8. The company modified plans for the initiation of the tesamorelin Phase III trial in nonalcoholic steatohepatitis and updated the progress for the oncology program, Nash tells investors in a research note. The analyst believes NASH program creates uncertainty and notes this Theratechnologies' commercial sales were weaker.

ShowHide Related Items >><<
THTX Theratechnologies
$3.75 /

+0.19 (+5.34%)

THTX Theratechnologies
$3.75 /

+0.19 (+5.34%)

01/20/21 National Bank
Theratechnologies price target lowered to C$3.75 from C$4 at National Bank
THTX Theratechnologies
$3.75 /

+0.19 (+5.34%)

THTX Theratechnologies
$3.75 /

+0.19 (+5.34%)

Conference/Events
Theratechnologies management to meet virtually with Cantor Fitzgerald » 04:55
07/22/21
07/22
04:55
07/22/21
04:55
THTX

Theratechnologies

$3.46 /

+0.14 (+4.22%)

Virtual Meeting to be…

Virtual Meeting to be held on July 22 hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
THTX Theratechnologies
$3.46 /

+0.14 (+4.22%)

THTX Theratechnologies
$3.46 /

+0.14 (+4.22%)

01/20/21 National Bank
Theratechnologies price target lowered to C$3.75 from C$4 at National Bank
THTX Theratechnologies
$3.46 /

+0.14 (+4.22%)

THTX Theratechnologies
$3.46 /

+0.14 (+4.22%)

Options
new option listings and one option delisting on July 21st » 08:30
07/21/21
07/21
08:30
07/21/21
08:30
ALZN

Alzamend Neuro

$5.24 /

-0.06 (-1.13%)

, ANPC

AnPac Bio

$4.16 /

+0.15 (+3.74%)

, APDN

Applied DNA Sciences

$5.26 /

+0.02 (+0.38%)

, ASX

ASE Technology

$8.63 /

+0.165 (+1.95%)

, AUTL

Autolus Therapeutics

$6.17 /

+0.08 (+1.31%)

, BCYC

Bicycle Therapeutics

$34.58 /

-0.11 (-0.32%)

, CRNX

Crinetics

$20.01 /

+0.51 (+2.62%)

, DLPN

Dolphin Entertainment

$8.10 /

+0.11 (+1.38%)

, DTM

DT Midstream

$41.16 /

+0.55 (+1.35%)

, ERTH

EarthShell

$65.20 /

+1.2 (+1.88%)

, KVSB

Khosla Ventures Acquisition Co. II

$10.55 /

+0.06 (+0.57%)

, LCTU

BlackRock U.S. Carbon Transition Readiness ETF

$49.81 /

+0.91 (+1.86%)

, NE

Noble Corp.

$21.01 /

+0.15 (+0.72%)

, NXTG

NextG Networks

$75.42 /

+1.01 (+1.36%)

, OPFI

OppFi

$9.95 /

-0.12 (-1.19%)

, PIO

Pioneer Group

$40.48 /

+0.56 (+1.40%)

, THTX

Theratechnologies

$3.32 /

+0.03 (+0.91%)

, VINO

Gaucho Group

$3.51 /

+0.3 (+9.35%)

, FGNA

FG New America Acquisition

/

+

New option listings for…

New option listings for July 21st include Alzamend Neuro Inc (ALZN), AnPac Bio Medical Science Company Ltd (ADS) (ANPC), Applied DNA Sciences (APDN), Advanced Semiconductor (ASX), Autolus Therapeutics PLC (ADS) (AUTL), Bicycle Therapeutics PLC (ADS) (BCYC), iShares MSCI ACWI Low Carbon Target ETF (CRBN), Crinetics Pharmaceuticals Inc (CRNX), Dolphin Entertainment Inc (DLPN), DT Midstream Inc (DTM), Invesco MSCI Sustainable Future ETF (ERTH), Market Vectors Environmental Services Fund (EVX), First Trust Dow Jones International Internet ETF (FDNI), Principal Millennials Index (GENY), First Trust NASDAQ Clean Edge Smart Grid Infrastructure Index Fd (GRID), Market Vectors Natural Resources (HAP), EG Shares India Consumer (INCO), Khosla Ventures Acquisition Company II (Class A Stock) (KVSB), Blackrock Us Carbon Transition Readiness Etf (LCTU), First Trust Indxx Innovative Transaction and Process (LEGR), Noble Corporation (NE), First Trust Index NextG ETF (NXTG), OppFi Inc (Class A Stock) (OPFI), ProShares Pet Care ETF (PAWZ), PowerShares Global Water Portfolio (PIO), Theratechnologies Inc (THTX), iShares MSCI Global Agriculture Producers (VEGI), Gaucho Group Holdings Inc (VINO), and SPDR S&P Internet ETF (XWEB). Option delistings effective July 21st include FG New America Acquisition Corp (Class A Stock) (FGNA).

ShowHide Related Items >><<
THTX Theratechnologies
$3.32 /

+0.03 (+0.91%)

OPFI OppFi
$9.95 /

-0.12 (-1.19%)

NE Noble Corp.
$21.01 /

+0.15 (+0.72%)

KVSB Khosla Ventures Acquisition Co. II
$10.55 /

+0.06 (+0.57%)

DTM DT Midstream
$41.16 /

+0.55 (+1.35%)

DLPN Dolphin Entertainment
$8.10 /

+0.11 (+1.38%)

CRNX Crinetics
$20.01 /

+0.51 (+2.62%)

BCYC Bicycle Therapeutics
$34.58 /

-0.11 (-0.32%)

AUTL Autolus Therapeutics
$6.17 /

+0.08 (+1.31%)

ASX ASE Technology
$8.63 /

+0.165 (+1.95%)

APDN Applied DNA Sciences
$5.26 /

+0.02 (+0.38%)

ANPC AnPac Bio
$4.16 /

+0.15 (+3.74%)

ALZN Alzamend Neuro
$5.24 /

-0.06 (-1.13%)

ALZN Alzamend Neuro
$5.24 /

-0.06 (-1.13%)

ANPC AnPac Bio
$4.16 /

+0.15 (+3.74%)

APDN Applied DNA Sciences
$5.26 /

+0.02 (+0.38%)

04/22/21 H.C. Wainwright
Applied DNA Sciences price target lowered to $13 from $14 at H.C. Wainwright
02/25/21 Roth Capital
Applied DNA Sciences issued new U.S. patent, says Roth Capital
02/19/21 Roth Capital
Roth Capital looks forward to Applied DNA's safeCircle driving NT revenue
02/12/21 Roth Capital
Applied DNA Sciences initiated with a Buy at Roth Capital
ASX ASE Technology
$8.63 /

+0.165 (+1.95%)

06/25/21 Nomura
ASE Technology downgraded to Neutral from Buy at Nomura
08/03/20 Credit Suisse
ASE Technology downgraded to Neutral from Outperform at Credit Suisse
AUTL Autolus Therapeutics
$6.17 /

+0.08 (+1.31%)

06/14/21 Jefferies
Autolus Therapeutics upgraded to Buy from Hold at Jefferies
03/10/21 Redburn
Autolus Therapeutics downgraded to Neutral from Buy at Redburn
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral with $9 target at JPMorgan
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral from Overweight at JPMorgan
BCYC Bicycle Therapeutics
$34.58 /

-0.11 (-0.32%)

07/15/21 Canaccord
Bicycle Therapeutics price target raised to $40 from $36 at Canaccord
07/14/21 Benchmark
Bicycle deal 'makes little sense' for Ionis, says Benchmark
07/13/21 William Blair
Bicycle collaboration a positive for Ionis, says William Blair
07/13/21 Piper Sandler
Bicycle Therapeutics price target raised to $46 from $39 at Piper Sandler
CRNX Crinetics
$20.01 /

+0.51 (+2.62%)

06/18/21 JPMorgan
Crinetics upgraded to Overweight ahead of data at JPMorgan
06/18/21 JPMorgan
Crinetics upgraded to Overweight from Neutral at JPMorgan
05/03/21 JonesTrading
Crinetics initiated with a Buy at JonesTrading
11/24/20 Piper Sandler
Crinetics could take 'sizable share' in $3.1B market, says Piper Sandler
DLPN Dolphin Entertainment
$8.10 /

+0.11 (+1.38%)

03/29/21 Maxim
Dolphin Entertainment price target raised to $28 from $10 at Maxim
DTM DT Midstream
$41.16 /

+0.55 (+1.35%)

07/15/21 Mizuho
DT Midstream initiated with a Buy at Mizuho
07/14/21
Fly Intel: Top five analyst initiations
07/14/21 JPMorgan
DT Midstream initiated with an Overweight at JPMorgan
07/01/21 Credit Suisse
DT Midstream initiated with an Outperform at Credit Suisse
ERTH EarthShell
$65.20 /

+1.2 (+1.88%)

KVSB Khosla Ventures Acquisition Co. II
$10.55 /

+0.06 (+0.57%)

LCTU BlackRock U.S. Carbon Transition Readiness ETF
$49.81 /

+0.91 (+1.86%)

NE Noble Corp.
$21.01 /

+0.15 (+0.72%)

NXTG NextG Networks
$75.42 /

+1.01 (+1.36%)

OPFI OppFi
$9.95 /

-0.12 (-1.19%)

06/28/21 Northland
FG New America Acquisition initiated with an Outperform at Northland
06/24/21 DA Davidson
OppFi initiated with a Buy at DA Davidson
PIO Pioneer Group
$40.48 /

+0.56 (+1.40%)

THTX Theratechnologies
$3.32 /

+0.03 (+0.91%)

01/20/21 National Bank
Theratechnologies price target lowered to C$3.75 from C$4 at National Bank
VINO Gaucho Group
$3.51 /

+0.3 (+9.35%)

FGNA FG New America Acquisition
/

+

THTX Theratechnologies
$3.32 /

+0.03 (+0.91%)

DLPN Dolphin Entertainment
$8.10 /

+0.11 (+1.38%)

CRNX Crinetics
$20.01 /

+0.51 (+2.62%)

BCYC Bicycle Therapeutics
$34.58 /

-0.11 (-0.32%)

AUTL Autolus Therapeutics
$6.17 /

+0.08 (+1.31%)

ASX ASE Technology
$8.63 /

+0.165 (+1.95%)

APDN Applied DNA Sciences
$5.26 /

+0.02 (+0.38%)

ANPC AnPac Bio
$4.16 /

+0.15 (+3.74%)

  • 08
    Apr
  • 17
    Feb
  • 10
    Feb
KVSB Khosla Ventures Acquisition Co. II
$10.55 /

+0.06 (+0.57%)

DLPN Dolphin Entertainment
$8.10 /

+0.11 (+1.38%)

KVSB Khosla Ventures Acquisition Co. II
$10.55 /

+0.06 (+0.57%)

FGNA FG New America Acquisition
/

+

DLPN Dolphin Entertainment
$8.10 /

+0.11 (+1.38%)

CRNX Crinetics
$20.01 /

+0.51 (+2.62%)

BCYC Bicycle Therapeutics
$34.58 /

-0.11 (-0.32%)

AUTL Autolus Therapeutics
$6.17 /

+0.08 (+1.31%)

ALZN Alzamend Neuro
$5.24 /

-0.06 (-1.13%)

LCTU BlackRock U.S. Carbon Transition Readiness ETF
$49.81 /

+0.91 (+1.86%)

Conference/Events
Theratechnologies management to meet virtually with Cantor Fitzgerald » 14:02
07/19/21
07/19
14:02
07/19/21
14:02
THTX

Theratechnologies

$3.29 /

-0.28 (-7.84%)

Virtual Meeting to be…

Virtual Meeting to be held on July 22 hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
THTX Theratechnologies
$3.29 /

-0.28 (-7.84%)

THTX Theratechnologies
$3.29 /

-0.28 (-7.84%)

01/20/21 National Bank
Theratechnologies price target lowered to C$3.75 from C$4 at National Bank
THTX Theratechnologies
$3.29 /

-0.28 (-7.84%)

Hot Stocks
Theratechnologies initiates search for partner for Phase 3 tesamorelin trial » 07:27
07/15/21
07/15
07:27
07/15/21
07:27
THTX

Theratechnologies

$3.68 /

+0.02 (+0.55%)

The Company announced…

The Company announced that discussions with the U.S. Food and Drug Administration and the European Medicines Agency regarding its proposed trial design and protocol for its Phase 3 clinical trial evaluating tesamorelin for the treatment of NASH are complete. In addition, the Company has initiated a search for a potential partner to help launch the program. Update on Phase 3 clinical trial evaluating tesamorelin in NASH: Discussions with the FDA and the EMA on the trial design are complete. The Phase 3 clinical trial will include participants in the U.S. and Europe. The Phase 3 clinical trial will be a multicenter, double-blind, placebo-controlled two-part study to evaluate the safety and efficacy of tesamorelin in liver-biopsy confirmed patients with NAS score of at least 4 and stage 2 or 3 fibrosis. The Phase 3 clinical trial will include a futility analysis that will be performed after approximately 400 patients have completed 18 months of treatment and have received a second liver biopsy. A supplemental Biologics Licence Application is expected to be filed after approximately 1,100 patients, including approximately 75 to 100 people living with HIV, have completed 18 months of treatment and have received a second liver biopsy. The primary endpoint will be NASH resolution and no worsening of fibrosis compared to placebo after 18 months as per FDA guidelines. Following potential approval, an additional 1,800 patients are expected to be enrolled, to continue measuring clinical outcomes over a period of five years. Based on regulatory discussions, the final Phase 3 clinical trial design will result in higher costs than what the Company had previously estimated. As a result of the total cost of the Phase 3 clinical trial, the Company is now evaluating its options to best execute its late-stage development program, including seeking a potential partner. An external U.S.-based biopharma advisory firm has been retained to assist in identifying a potential partner. Partner identification and negotiations will alter the initiation of the Phase 3 clinical trial that was previously expected to begin in the third quarter of calendar year 2021.

ShowHide Related Items >><<
THTX Theratechnologies
$3.68 /

+0.02 (+0.55%)

THTX Theratechnologies
$3.68 /

+0.02 (+0.55%)

01/20/21 National Bank
Theratechnologies price target lowered to C$3.75 from C$4 at National Bank
THTX Theratechnologies
$3.68 /

+0.02 (+0.55%)

Hot Stocks
Theratechnologies expects cash to fund obligations for at least next 12 months » 07:25
07/15/21
07/15
07:25
07/15/21
07:25
THTX

Theratechnologies

$3.68 /

+0.02 (+0.55%)

At period-end May 31,…

At period-end May 31, 2021, the Company had $56,714,000 in cash, bonds and money market funds, and remained virtually unchanged from February 28, 2021. At this time, the current cash, bonds and money market funds are sufficient to fund the Company's operations to meet its current obligations for at least the next twelve months.

ShowHide Related Items >><<
THTX Theratechnologies
$3.68 /

+0.02 (+0.55%)

THTX Theratechnologies
$3.68 /

+0.02 (+0.55%)

01/20/21 National Bank
Theratechnologies price target lowered to C$3.75 from C$4 at National Bank
THTX Theratechnologies
$3.68 /

+0.02 (+0.55%)

Earnings
Theratechnologies reports Q2 EPS (7c) vs. (8c) last year » 07:24
07/15/21
07/15
07:24
07/15/21
07:24
THTX

Theratechnologies

$3.68 /

+0.02 (+0.55%)

Reports Q2 revenue…

Reports Q2 revenue $17.79M vs. $17.16M last year. "The first half of 2021 has been marked by progress across our R&D pipeline of novel compounds. Our Phase 1 clinical trial of TH1902 for the treatment of sortilin-expressing cancers progressed as planned during the quarter and we believe that we have developed a targeted peptide-drug conjugate that may potentially transform the way cancer is treated. In NASH, we concluded regulatory discussions in the U.S. and EU and now have a ready-to-proceed Phase 3 clinical trial design," said Paul Levesque, President and CEO, Theratechnologies. "Given the additional resources required to conduct the Phase 3 clinical trial in NASH, we are evaluating opportunities that will allow us to most effectively execute this program, including seeking a potential partner for late-stage development. While this will alter the planned timing of the Phase 3 clinical trial initiation, finding a strong partner could potentially add additional resources and capabilities that will be of great value as we advance this exciting program toward a potential approval," added Mr. Levesque.

ShowHide Related Items >><<
THTX Theratechnologies
$3.68 /

+0.02 (+0.55%)

THTX Theratechnologies
$3.68 /

+0.02 (+0.55%)

01/20/21 National Bank
Theratechnologies price target lowered to C$3.75 from C$4 at National Bank
THTX Theratechnologies
$3.68 /

+0.02 (+0.55%)

Over a month ago
Hot Stocks
Theratechnologies appoints Frank Holler to board of directors » 07:36
06/23/21
06/23
07:36
06/23/21
07:36
THTX

Theratechnologies

$3.76 /

-0.08 (-2.08%)

Theratechnologies…

Theratechnologies announced the appointment of Frank Holler as a new independent member to its board of directors. Frank Holler is currently President & CEO of Ponderosa Capital.

ShowHide Related Items >><<
THTX Theratechnologies
$3.76 /

-0.08 (-2.08%)

THTX Theratechnologies
$3.76 /

-0.08 (-2.08%)

01/20/21 National Bank
Theratechnologies price target lowered to C$3.75 from C$4 at National Bank
THTX Theratechnologies
$3.76 /

-0.08 (-2.08%)

Conference/Events
Theratechnologies to host conference call » 10:25
06/21/21
06/21
10:25
06/21/21
10:25
THTX

Theratechnologies

$3.82 /

+0.12 (+3.24%)

Management discusses…

Management discusses SORT1+ Technology for treatment of all Sortilin-Expressing Cancers on a conference call to be held on June 21 at 11 am. Webcast Link

ShowHide Related Items >><<
THTX Theratechnologies
$3.82 /

+0.12 (+3.24%)

THTX Theratechnologies
$3.82 /

+0.12 (+3.24%)

01/20/21 National Bank
Theratechnologies price target lowered to C$3.75 from C$4 at National Bank
THTX Theratechnologies
$3.82 /

+0.12 (+3.24%)

Hot Stocks
Theratechnologies announces preclinical findings for TH1902 » 09:33
06/21/21
06/21
09:33
06/21/21
09:33
THTX

Theratechnologies

$3.69 /

+0.09 (+2.50%)

Theratechnologies…

Theratechnologies announced new preclinical in vivo findings on the anti-metastatic effect and tolerability of its novel investigational proprietary peptide-drug conjugate, TH1902. These results demonstrate that TH1902 has better anti-metastatic activity when compared to docetaxel alone when administered at an equimolar concentration in a lung metastasis cancer model expressing the sortilin receptor. Metastasis is a form of cancer that has spread from its original site to a distant site or organ where it grows or metastasizes. It is well-known that the survival rate for metastatic cancer is low. The Company intends to present these findings at an upcoming scientific meeting.

ShowHide Related Items >><<
THTX Theratechnologies
$3.69 /

+0.09 (+2.50%)

THTX Theratechnologies
$3.69 /

+0.09 (+2.50%)

01/20/21 National Bank
Theratechnologies price target lowered to C$3.75 from C$4 at National Bank
THTX Theratechnologies
$3.69 /

+0.09 (+2.50%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.